Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Summit Therapeutics Summit Therapeutics (US:SMMT) Businesswire·2026-07-22 18:30

公司核心进展 - Summit Therapeutics Inc (纳斯达克: SMMT) 公布了其全球III期HARMONi临床试验中新型、潜在同类首创研究性双特异性抗体ivonescimab的更新总生存期分析结果 [1] - 与单独化疗相比，ivonescimab联合铂类双药化疗在试验中继续显示出积极的总生存期趋势，并且在亚洲和西方患者中具有一致的疗效和安全性特征 [1]

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study - Reportify